AI lifestyle help vs tirzepatide for obesity and new diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study compares an AI-powered lifestyle program to a medication called tirzepatide for helping people with obesity and newly diagnosed type 2 diabetes lose weight and manage their blood sugar. It aims to find which approach works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You were diagnosed with type 2 diabetes within the last 3 years and have not taken any diabetes medications for at least 3 months.
- Your body mass index (BMI) is between 28 and 40 kg/m².
- Your weight has stayed about the same (no more than a 5% change) in the last 3 months.
- You are not pregnant, breastfeeding, or planning to become pregnant in the next year, and you are willing to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This study tests whether a new injectable medication called HDM1005 works as well as tirzepatide (a GLP-1 drug) for weight loss in adults with obesity but no diabetes. Both medications work similarly in the body to help control appetite and weight.
This study tests a new medication called tirzepatide, given at carefully adjusted doses, to help people with obesity lose weight while reducing unwanted side effects. Tirzepatide is a newer injectable medicine that helps control appetite and blood sugar.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This study tests an experimental medication called ARO-INHBE in adults with obesity, including those who also have type 2 diabetes. The goal is to see if it helps with weight loss and is safe.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.